Environment

To help get ahead of disease and deliver real human health impact we need to look broadly and deeply at the interconnections of climate, nature and health.

We’re committed to a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

Our sustainability goals and targets

Person smiling while entering their home
As a global biopharma leader, we want to play our full part in protecting and restoring the planet’s health, in order to protect and improve people’s health. Improving the environmental sustainability of our business makes us more resilient, so we can deliver the products that patients rely on.
Emma Walmsley

Emma Walmsley

CEO

Scientific evidence is increasingly demonstrating how climate change and nature loss are impacting the world and human health. For example, human health is under threat from air pollution, diseases that pass from animals to humans and threats to water security. Climate and nature changes are testing the resiliency of healthcare systems.

As a global biopharma leader, addressing our environmental impact is fundamental to our purpose. That’s why we have set ambitious climate and nature targets.

Net zero impact on climate

Our climate action targets
  • 100% renewable electricity by 2025 (Scope 2)
  • 80% reduction in carbon emissions and investment in nature-based solutions for the remaining 20% of our footprint by 2030 (all scopes)*
  • Net zero emissions across our full value chain by 2045 (all scopes)

* Previously stated as net zero by 2030, and updated to align with the SBTI Net Zero Standard. See page 16 of the 2022 ESG Performance Report for more context.

Contributing to nature positive world

Our nature action targets

Freshwater

  • 100% of our sites to achieve good water stewardship by 2025 and reduce overall water use by 20% by 2030
  • Water neutral in operations and with key suppliers in water-stressed regions by 2030
  • Zero impact active pharmaceutical ingredient levels1 for all sites and key suppliers by 2030*

 

Land
  • Positive impact on biodiversity at all sites2 by 2030
  • 100% of agricultural and forestry derived materials sustainably sourced and deforestation free by 20303*

 

Oceans
  • 100% of marine-derived materials sustainably sourced by 2030

 

Atmosphere
  • 100% renewable electricity by 2025 (Scope 2)*
  • 80% reduction in carbon emissions across our full value chain by 2030*
  • Net zero carbon emissions across our full value chain by 2045*

 

Waste and materials
  • Zero operational waste4, including eliminating single use plastics5  by 2030*
  • 10% waste reduction from supply chain by 2030
  • 25% environmental impact reduction for our products and packaging by 2030

 

1Below the predicted no-effect level

2GSK-owned sites

3 Target updated in December 2021 to reflect priority materials

4 Including a 20% reduction in routine hazardous and non-hazardous waste

5 Where regulatory obligations allow, and excluding plastics which are critical to product discovery and development and health & safety

* Linked with the remuneration of our senior leaders

Reporting

We report progress against these underlying targets and goals on an annual basis, disclosed as part of our Annual Report and ESG reporting.

Teal-coloured river running across a tropical forest

Find out about our sustainability focus areas

Wind turbines

Climate

We are committed to net zero impact on climate across our entire value chain.

Child watering flowers

Water

Fresh water is key to the sustainable production of our medicines and vaccines.

Lab worker performing an experiment

Materials and waste

We are working hard across our value chain to reduce our materials and waste.

Person outdoors planting previously potted plant into the ground

Biodiversity

Biodiversity is key to achieving our nature goals across every aspect of our business.

What sustainability means for GSK

Delivering our sustainability targets is not just important for planetary and human health. It’s important for us as a business in terms of supporting growth, mitigating risk and getting ahead of legislation.

As countries around the world commit to low carbon healthcare systems, we are seeing increasing demand from customers, healthcare practitioners and patients for sustainable products. We understand this is an issue that many of our people are passionate about.

  • Delivering our goals

    • Delivering our climate and nature goals is now a fundamental part of our business. That’s why we continue to integrate sustainability into our operations.

    Achieving these new goals will require collaboration across our entire value chain – from discovery to disposal - and so we will continue to work closely on sustainability with our suppliers, customers, consumers, patients and external experts.

  • Resilience and adaptation

    • Beyond the impact we have on the environment, we are also helping to adapt and build resilience to the new health challenges that a changing environment will bring. We’re doing this by developing and manufacturing new medicines and vaccines for the diseases most affected by climate change. We’re also playing our part in building strong health systems, especially in locations that are most vulnerable to climate-related shocks.

    Global health

  • Our climate goal

    • Our climate strategy covers the full value chain of emissions reductions across our own operations, our supplier base and emissions from patient use of our products.

    We have set out a projected pathway to reaching net zero carbon by 2030 and identified the key activities that will help us reach this goal. 

    The Science Based Targets Initiative has accredited that our climate targets align to a 1.5° pathway. We have joined the Race to Zero: a global UN campaign, which aims to build momentum around the shift to a decarbonised economy. We have also disclosed climate change risks aligned to the Taskforce for Climate-related Financial Disclosure (TCFD) since 2019 – see our climate related financial disclosure as part of our Annual report.

  • Our nature goal

    • The science is clear that nature loss is happening at a faster rate than at any time in human history.6 Human health relies on the fundamentals of nature: clean air and fresh water. To protect human health and get ahead of disease, we need to protect nature7.

    We are a part of the first group of companies to be working with the Science Based Target Network (SBTN) to set validated science-based targets for nature, starting with targets for freshwater and land, followed by targets for oceans and biodiversity. These targets will focus on locations across our value chain where nature is particularly under pressure. We expect to have science-based targets for nature in 2024.

    Our plan to contribute to a nature positive world is in line with the goal of the post 2020 Global Biodiversity Framework to halt and reverse biodiversity loss by 2030.

    Our approach is through four focus areas which are aligned to the ‘realms’ of nature as defined by TNFD and SBTN8. These are the major components of the natural world – freshwater, land, oceans and atmosphere – including the biodiversity of living species across these realms.

    To find out more about our how we plan to deliver these goals across our business, please see our water, materials and waste, and biodiversity pages. 

    6Global Assessment Report on Biodiversity and Ecosystem Services | IPBES secretariat

    7Biodiversity and Health (who.int)

    8Definitions of nature - TNFD

More on our sustainability commitments

GSK Sustainable Sourcing Standards (PDF - 880KB)

Understanding Impact And Dependencies On Nature (PDF - 4.8MB)

GSK Sustainability And Global Health Update At COP27 (PDF - 100.6KB)

Sharing our journey to net zero and nature positive for a healthier future (PDF - 924.3KB)

GSK Position On Environmental Sustainability (PDF - 350KB)

GSK Environmental Action Report 2022 (PDF - 1.8MB)

Environmental sustainability goals infographic (PDF - 90.6KB)

Continue to Product governance